Subscribe
shutterstock_1846161670_jhvephoto
JHVEPhoto / Shutterstock.com
2 September 2022AmericasStaff Writer

Novo Nordisk makes $1.1bn bid for biopharma company

Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Novo Nordisk and Sandoz settle Victoza patent suit
24 March 2022   Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.
Americas
Pfizer bolsters haematology expertise with $5.4bn deal
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Big Pharma
Big pharma co buys $16.6bn for heart tech company
2 November 2022   Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Generics
Novo Nordisk and Sandoz settle Victoza patent suit
24 March 2022   Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.
Americas
Pfizer bolsters haematology expertise with $5.4bn deal
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Big Pharma
Big pharma co buys $16.6bn for heart tech company
2 November 2022   Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division

More on this story

Generics
Novo Nordisk and Sandoz settle Victoza patent suit
24 March 2022   Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.
Americas
Pfizer bolsters haematology expertise with $5.4bn deal
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Big Pharma
Big pharma co buys $16.6bn for heart tech company
2 November 2022   Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent